Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Darien, CT
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Darien, CT
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Quincy, MA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Quincy, MA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Hattiesburg, MS
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Eatontown, NJ
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Franklin, TN
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Bennington, VT
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Bennington, VT
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Williamsburg, VA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Williamsburg, VA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Costa Mesa, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Fresno, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
La Jolla, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Santa Ana, CA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Delray Beach, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Hialeah, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Miami, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Orlando, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Tampa, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
W Palm Beach, FL
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
W Palm Beach, FL
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Cedarhurst, NY
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Charlotte, NC
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Tulsa, OK
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Austin, TX
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated:  2/12/2016
mi
from
Adelaide,
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Status: Enrolling
Updated: 2/12/2016
mi
from
Adelaide,
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Stanford University
mi
from
Stanford, CA
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
University of Miami
mi
from
Miami, FL
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Florida Hospital Orlando
mi
from
Orlando, FL
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Augusta University
mi
from
Augusta, GA
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
University of Kentucky Medical Center
mi
from
Lexington, KY
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
University of Kentucky Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
University of Louisville
mi
from
Louisville, KY
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Boston University
mi
from
Boston, MA
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Boston University
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Summa Health System
mi
from
Akron, OH
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Summa Health System
mi
from
Akron, OH
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
University of Cincinnati
mi
from
Cincinnati, OH
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Case Western Reserve University School of Medicine
mi
from
Cleveland, OH
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Case Western Reserve University School of Medicine
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Cleveland Clinic
mi
from
Cleveland, OH
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Pennsylvania State University
mi
from
Hershey, PA
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Pennsylvania State University
mi
from
Hershey, PA
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
University of Pittsburgh Medical Center Health System
mi
from
Pittsburgh, PA
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
University of Pittsburgh Medical Center Health System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Palmetto Health Richland
mi
from
Columbia, SC
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Palmetto Health Richland
mi
from
Columbia, SC
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Chattanooga Center for Neurologic Research
mi
from
Chattanooga, TN
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Chattanooga Center for Neurologic Research
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
University of Utah
mi
from
Salt Lake City, UT
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Northwestern University
mi
from
Chicago, IL
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Henry Ford Health System
mi
from
Detroit, MI
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated:  2/12/2016
Oregon Health and Sciences University
mi
from
Portland, OR
Study to Examine the Effects of MultiStem in Ischemic Stroke
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke
Status: Enrolling
Updated: 2/12/2016
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials